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Purpose: Osteosarcoma is the most prevalent bone tumor in children and adolescents. 
At present, the mechanisms of initiation, maintenance, and metastasis are poorly 
understood. The purpose of this study was to identify relevant molecular targets in the 
pathogenesis of osteosarcoma. 
 
Experimental Design: Tumor chemonaive osteoblastic populations and paired control 
normal osteoblasts were isolated and characterized phenotypically from seven 
osteosarcoma patients. Global transcriptomic profiling was analyzed by robust 
microarray analysis. Candidate genes were confirmed by real-time PCR and organized 
in molecular pathways. EBF2 and osteoprotegerin (OPG) levels were determined by 
real-time PCR and OPG protein levels were assessed by ELISA. Immunohistochemical 
analysis was done in a panel of 46 osteosarcoma samples. Silencing of EBF2 was 
achieved by lentiviral transduction of short hairpin RNA. Apoptosis was determined by 
caspase-3/7 activity. 
 
Results: A robust clustered transcriptomic signature was obtained in osteosarcoma. 
Transcription factor EBF2, a known functional bone regulator, was among the most 
significantly overexpressed genes. Immunohistochemical analysis showed that 
osteosarcoma is expressed in 70% of tumors analyzed. Because EBF2 was shown 
previously to act as a transcriptional activator of OPG, elevated levels of EBF2 were 
associated with high OPG protein levels in osteosarcoma samples compared with 
normal osteoblastic cells. Knockdown of EBF2 led to stunted abrogation of OPG levels 
and increased sensitivity to tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL)–induced apoptosis. 
 
Conclusions: These findings suggest that EBF2 represents a novel marker of 
osteosarcoma. EBF2 up-regulation may be one of the mechanisms involved in the high 
levels of OPG in osteosarcoma, contributing to decrease TRAIL-induced apoptosis and 
leading to TRAIL resistance.  
 INTRODUCTION 
  
Osteosarcoma is the most common primary malignant tumor of bone characterized by 
production of osteoid and a high propensity to metastasize (1). It most frequently occurs 
in the second decade of life with 60% of patients ages <25 years, whereas 30% of 
osteosarcoma occurs in patients ages >40 years. 
  
At present, the standard treatment for high-grade osteosarcoma includes neoadjuvant 
chemotherapy followed by surgical resection and postoperative chemotherapy. Several 
clinical factors have been related to survival, including the presence of metastatic 
disease and the histologic response to preoperative chemotherapy. Despite the efforts in 
new therapeutic modalities, survival remains 65% to 70% in patients with 
nonmetastatic disease (2, 3). 
 
Osteogenic sarcoma affecting children and adolescents mostly includes sporadic cases 
of unknown etiology, with a peak of incidence during the pubertal growth spurt. In this 
group of classic, high-grade osteosarcoma, few, if any, genetic alterations are present in 
a substantial subset of these tumors and the frequency of the alterations usually varies 
between studies depending on the design and the specimens included (4). About 70% of 
osteosarcomas have altered karyotypes, being the gain of chromosome 1, loss of 9, 13 
(RB1 gene), and 17 (TP53), and structural aberrations affecting chromosomes 11, 19, 
and 20 the most frequently encountered chromosomal aberrations (5–7). 
 
Histologically, the predominant cell type displays typical osteoid secretion, with 
different degrees of fibroblastic and osteochondroblastic components. This cellular 
heterogeneity arises from the high plasticity of the mesenchymal cell lineage from 
which mature osteoblasts derive through a tightly regulated process (8) driven by 
several factors, which induce the expression of bone markers including osteocalcin, and 
several bone matrix proteins including collagen type I, osteopontin, and bone 
sialoprotein (9). 
 
At present, global transcriptomic profiling of human osteosarcoma remains highly 
divergent among studies (10–13). Several major explanations could account for these 
conflicting findings. First, most of the studies rely on surgical specimens, or paraffin-
embedded material, where the tumor remains surrounded by nontumoral cells, including 
inflammatory components, which highly influence transcriptomic profiling. Second, 
surgical specimens most frequently represent advanced lesions in which chromosomal 
instability leads to a heterogeneous constellation of cytogenetic alterations within the 
same tumor. Third, some of the studies have been done using commercial cell lines, 
which do not totally recapitulate all features of the original tumor from which they were 
derived. Fourth, several of the studies include specimens belonging to different 
etiopathologic subgroups. 
 
To overcome these limitations, we have focused on the classic high-grade, sporadic 
osteosarcoma cases and we have undertaken a different approach by isolating and 
characterizing several human chemonaive cell populations derived from primary 
osteosarcomas and their paired-normal primary osteoblastic counterparts. With the long-
term goal of understanding the molecular mechanisms and to unveil commonly altered 
molecular pathways, we have used this set of samples to perform global transcriptomic 
profiling. Using this approach, we found a robust clustering that revealed a novel gene 
subset that was further validated by quantitative real-time PCR (RT-PCR). A frequent 
alteration in the mechanisms of apoptosis was observed in tumor cells. We identified 
and functionally validated EBF2 as a pathway altered in osteosarcoma. Functional 
assays showed a common resistance to tumor necrosis factor (TNF)–related apoptosis-
inducing ligand (TRAIL)–mediated apoptosis. Elevated levels of the transcription factor 
EBF2 in tumor cells were correlated with high levels of osteoprotegerin (OPG) 
presumably by direct binding to its promoter (14). In turn, increased levels of this decoy 
receptor accounted for the resistance to TRAIL-mediated apoptosis. These findings 
identified EBF2 as a novel marker of osteosarcoma and revealed a novel mechanistic 






The mechanisms of osteosarcoma pathogenesis are largely unknown. Here we identified 
EBF2, a known transcription factor of osteoprotegerin (OPG), as a relevant marker up-
regulated in osteosarcoma. Silencing of EBF2 led to a concomitant decrease in OPG 
levels in osteosarcoma cells and a decreased resistance to apoptosis induced by tumor 
necrosis factor–related apoptosis–inducing ligand. These findings involve EBF2 up-
regulation as one of the mechanisms contributing to high OPG levels in osteosarcoma. 
It might be possible to use EBF2 as a novel target in combination with anti–tumor 
necrosis factor–related apoptosis-inducing ligand therapy to increase the clinical benefit 




MATERIALS AND METHODS 
 
Patients and clinical samples 
 
Primary tumor samples were obtained by needle biopsy from seven high-grade 
osteosarcomas before induction chemotherapy, and paired-normal osteoblasts were 
isolated when patients underwent surgery. Small (1 X 1 X 0.5 cm) biopsies of normal 
trabecular bone were obtained beyond the marginal resection border (Table 1). All 
patients were treated at the Pediatric Oncology Unit of the University Hospital of 
Navarra. All the samples were obtained with written informed consent from patients 
and/or their parents and the protocol was approved by the local ethics committee. 
 
Human osteoblasts were isolated according to procedures we have published previously 
(9). Briefly, needle biopsy specimens were cleaned of soft tissue under a dissecting 
microscope. The remaining bone chips were washed with PBS and treated with 250 
units/mL collagenase and DNase in α-MEM for 2 h. Following digestion, bone debris 
were separated by using a 70 µm nylon mesh. Cells were precipitated by centrifugation, 
washed several times to remove excess collagenase and DNase, and placed in α -MEM 
containing 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, and 100 
µg/mL streptomycin. The remaining bone chips were also cultured in the same medium. 
After 4 weeks, outgrowing osteoblasts were subcultured and characterized. All 
experiments were done with 1 to 5 passages normal osteoblastic cells, whereas tumoral 
cells were passed between 20 and 40 times; in all cases, cells were 90% confluent and in 
logarithmic growth phase. Small fractions of cells were routinely seeded and 
histochemical determination of alkaline phosphatase activity was done. The cell lines 
derived from the tumors were designed as the number of the patient followed by B 
(biopsy) and the paired-normal cell lines by N (normal). 
Characterization of the osteoblastic phenotype  
 
All normal and tumor-derived cell lines were tested for the expression of alkaline 
phosphatase (Sigma-Aldrich). Additional markers of the osteoblastic lineage, collagen 
α1 type I, osteopontin, bone sialoprotein, and osteocalcin, were tested by 
semiquantitative RT-PCR using previously described primers and conditions (15). 
 
 
Tumorgenotypic characterization  
 
Tumor-derived and normal bone cell lines were checked for mutations in genes that are 
frequently mutated in osteosarcoma. Exons 5 to 9 of TP53 were analyzed by direct 
sequencing of the PCR products and loss of heterozygosity was determined by the 
analysis of a VNTR marker located in intron 1 of the gene. Loss of heterozygosity at the 
RB1 gene was determined by the use of repeat polymorphisms located in introns 2 
(D13S153) and 20 (Rb1.20) of the gene and comparison of the allele patterns in normal 
and tumor samples. 
 
 
Proliferation and apoptosis assay  
 
Cell proliferation was assessed by MTT assay according to the manufacturer's 
recommendations (Roche Applied Science). Cells were seeded in 96-well plates at a cell 
density of 103 per well and then cultured for 2, 4, and 6 days. Apoptosis was analyzed in 
triplicate assays with the Caspase-Glo-3/7 Assay (Promega Biotech Ibérica). Briefly, 
1,000 cells per well were seeded in 96-well plates, and after incubation with α-MEM 
supplemented with 0.4% fetal bovine serum for 24 h, the assay was initiated. Cells were 
incubated for 24 h with TNF-α (25 ng/mL), TRAIL (50 ng/mL), and OPG (1 μg/mL) or 
their combination. After incubation, luminescence of each sample was measured in a 
plate-reading luminometer (Sunrise Remote) at 485/527 nm. Results were plotted as the 




RNA extraction for microarray analysis  
 
RNA was isolated from 1 X 106 cells in logarithmic growth phase using the Qiagen 
RNeasy Mini Kit. Quality of the RNA was determined with a bioanalyzer (2100; 
Agilent Technologies) and the amount of RNA was established using a 
spectrophotometer (NanoDrop). Samples were stored at -80°C until RNA hybridization. 
Labeling and hybridization of the HG-U133A chips were done by Progenika 
Biopharma. The set corresponds to 14 samples (7 control bones and 7 osteosarcomas) 
derived from human osteosarcoma populations and their paired osteoblast control cells 
were obtained from the same patients. 
 
 
Microarray data analysis: normalization, signal calculation, significant differential 
expression, and sample/gene profiles clustering  
        
Microarray data analysis was done using the following strategy and methods: RMA 
algorithm was used for background correction, intra- and intermicroarray normalization, 
and expression-signal calculation (16–18). Once calculated, the absolute expression 
signal for each gene (the signal value for each probe-set) in each microarray, 
significance analysis of microarrays method (19), was applied to calculate significant 
differential expression and find the gene probe-sets that characterized the osteosarcoma 
samples. The method uses permutations to achieve robust statistical inference of the 
most significant genes and provides P values adjusted to multiple testing using false 
discovery rate (19). A cutoff of false discovery rate < 0.05 was used for all the 
differential expression calculations (20). 
 
Following selection of the differentially expressed gene probe-sets, the corresponding 
matrix of expression values from all microarray hybridization samples (14 in total) was 
analyzed using the HCLUST clustering algorithm (21). This algorithm performs 
hierarchical cluster analysis with complete linkage to find similar expression profiles 
between gene probe-sets based on their correlation values along all the sample 
microarrays analyzed (calculated using the Pearson correlation coefficient). This is a 
semisupervised classification because only the genes with significant differential 
expression are included in HCLUST algorithm. We applied all these methods using R7 
and Bioconductor as main computational and bioinformatic tools.8 
 
 
Gene expression validation by Micro Fluidic Cards  
 
To validate the results obtained, we performed TaqMan verification for expression of 96 
selected genes in all 14 cell lines used in the previous experiments and 14 additional 
samples (5 normal and 9 tumoral) using an Applied Biosystems 7900HT Micro Fluidic 
Card System (Applied Biosystems). For the design of the test plates, probes were 
selected as partially overlapping with the Affymetrix probe-sets or at a 100-bp distance 
avoiding, when possible, intronic sequences. These criteria were fulfilled in 41 of 96 
designed probes. For some genes (TLE3, PCBP1, PCBP2, EBF2, PHLDA1, OPG, and 
ADNP), gene expression was additionally tested by conventional semiquantitative RT-
PCR in the same battery of osteosarcoma cell samples. Estimation of mRNA levels was 
done relative to GAPDH as an internal reference in all cases and the quantity of starting 
material and the number of PCR cycles were optimized to ensure product yield within 
the linear range of amplification. 
 
 
Gene expression validation by quantitative RT-PCR with TaqMan probes  
 
Total RNA was isolated from confluent cultures using Trizol RNA (2 μg), DNase I 
treated, and reverse transcribed using SuperScript II reverse transcriptase and random 
primers. For RT-PCR analysis of the gene expression, 1:80 dilution of this reaction was 
used with SYBR Green I dye chemistry. PCR product was monitored using a Gene 
Amp 7300 sequence detection system (Applied Biosystems). The mean cycle threshold 
value (Ct) from triplicate samples was used to calculate gene expression. PCR products 
were normalized to GAPDH levels (22). Primers for OPG and EBF2 were obtained 





Lentiviral vectors containing short hairpin RNA for EBF2 were obtained from shRNA 
Mission (Sigma). To obtain viral particles, packaging cells were transfected with 8 μg 
DNA for each construct by calcium phosphate method. Empty vector was used to obtain 
mock infective viral particles. Two days after transfection, supernatants were 
centrifuged for 10 min at 600 × g and filtered through 0.45 μm pore cellulose acetate 
filter. For transduction infection, 595B cells were seeded at 1 X 105 and incubated 
overnight with viral supernatants in the presence of 4 μg/mL polybrene (Sigma). Forty-
eight hours post-infection, cell populations were incubated in medium containing the 
appropriate antibiotic for 2 additional weeks. Antibiotic-resistant pools were expanded 





Osteosarcoma tissue microarray was developed using archival samples of the University 
Hospital in our institution. The tissue microarray contains 233 tissue spots derived from 
46 patients. It includes normal bone (17.2%), osteosarcomas at diagnosis (26.3%), after 
induction with chemotherapy (11.1%), relapsed tumors (10.1%), and metastasis 
(35.4%). Formalin-fixed, paraffin-embedded tissue sections were used for the 
immunohistochemical procedures. Paraffin was removed from the tissues and the 
sections were hydrated through a graded series of ethanol. Endogenous peroxidase 
activity was quenched with 3% hydrogen per-oxidase for 10 min. Microwave antigen 
retrieval was carried out with EDTA (0.5 mmol/L, pH 8) for 2 × 15 min. Nonspecific 
binding sites were blocked with 5% goat normal serum in TBS-Tween 20 (washing 
buffer; DAKO) for 30 min. Sections were incubated with anti-EBF2 antibody (Genway) 
overnight at 4°C. The working dilution was 1:300. After rinsing with TBS, sections 
were incubated with polyclonal Envision complex (DAKO). The peroxidase activity 
was shown by 3,3′-diaminobenzidine. Finally, sections were washed in water, lightly 
counterstained with hematoxylin, dehydrated, and mounted in DPX. 
 
 
Statistical analysis  
 
Gene expression levels were compared with the Mann-Whitney U test or the Kruskal-
Wallis test. The statistical analysis was done with the SPSS software version 15.0 
(Statistical Package for the Social Sciences). In all cases, statistical significance was 







Isolation and characterization of chemonaive cell populations  
 
Tumor cell populations were obtained from patients diagnosed with high-grade 
osteosarcoma. Clinical features of the patients are summarized in Table 1. This subset 
included tumors with different degree of histologic differentiation (Fig. 1A). In all 
cases, cultures were successfully obtained at diagnosis from a “true-cut” needle biopsy 
of 0.5 mm. Tumor cells were isolated, amplified, and cultured from 15 to 22 passages, 





To characterize the isolated subpopulations, we screened for classic altered genes, TP53 
and RB1. In 2 of the 7 tumor samples, we detected alterations in TP53. These 
alterations included a sample with a hemizygous deletion plus a mutation in exon 8 
(C277Y). The other tumor showed a hemizygous deletion plus a mutation in exon 7 
(S241Y; Supplementary Fig. S1). 
 
Microscopic examination revealed heterogeneous morphology among different tumor 
cell lines (Fig. 1B). To test the degree of osteoblastic differentiation, genes of the 
osteoblastic phenotype were tested by semiquantitative RT-PCR in both normal and 
tumor-derived cell lines. In all cases, we detected expression of collagen α1 type I, 
osteopontin, bone sialoprotein, and osteocalcin in all cell lines. However, the expression 
of osteocalcin was decreased in tumors cells compared with paired-normal osteoblasts 
(Supplementary Fig. S2). On incubation with 1,25-dihydroxyvitamin D3, similar levels 
of osteocalcin were reached compared with normal osteoblasts (data not shown). 
Similarly, alkaline phosphatase activity was also lower in primary tumor cell lines 
compared with normal bones (Supplementary Fig. S2). These data suggest that tumor-
derived cell lines represent populations of the osteoblastic lineage, which display a 
perturbed differentiation program. 
 
 
Proliferation and apoptosis  
 
To explore the mechanisms of growth and resistance, we examined the proliferation and 
resistance to apoptosis of transformed cells compared with paired-normal osteoblasts. 
MTT assay revealed that cell kinetics differed among samples. Several samples tumor 
cell populations showed a lower proliferation than paired-normal osteoblasts 
(Supplementary Fig. S3). More importantly, apoptosis stimuli, either by incubation in 
serum-free medium or with VP-16, a DNA damage compound (23), induced cell death 
in both tumor and normal cell lines. However, tumor-derived cell populations displayed 
different levels of resistance to apoptosis than paired-normal osteoblasts (data not 
shown). These findings indicate that transformed cells showed altered mechanisms of 
cell proliferation and apoptosis. 
 
 
Global transcriptomic profiling 
 
Stringent bioinformatic processing revealed a robust set of differentially expressed 
significant genes, including 136 gene probe-sets that corresponded to 122 distinct 
human genes, which had a fold-change ratio above 2.8 times for the up-regulated and 
below 2.8 times for the down-regulated. The selected 136 gene probe-sets were used to 
perform a semisupervised clustering with all the 14 samples that revealed clear profiles 
with 116 overexpressed and 20 repressed gene probe-sets in the tumor samples. To 
represent the data in a heat map (Fig. 2), we only included 105 gene probe-sets that 
corresponded to known annotated human genes. In this clustering, 87 gene probe-sets 
were over-expressed in the tumor samples and 18 were repressed. A complete list of the 
identities of these genes can be found in Supplementary Table S1. 
 
To confirm the involvement of the selected genes in osteosarcoma carcinogenesis, we 
performed TaqMan verification for expression of 96 selected genes in a total of 28 
samples: 14 cell lines used in the previous experiments and 14 additional samples (5 
normal, 4 primary tumor, and 5 osteosarcoma lung metastases). In the list of genes, 93 
were target genes, 4 of which were excluded due to absence of amplification (CPS1, 
HNF4A, PDE4C, and NR2E1) and 3 were housekeeping genes used for normalization: 
GAPDH, RER1, and DNCL2A. The genes that were validated (associated P < 0.05) or 
that showed a tendency to be involved in the model (associated P = 0.05-0.09) are 
included in Table 2. 
 
For some genes (TLE3, PCBP1, PCBP2, TNFRSF6, EBF2, OPG, PHLDA1, and 
ADNP), gene expression was additionally tested by TaqMan quantitative PCR analysis. 
In all cases, the result of the validation in the Micro Fluidic Card System was the same 
when using the gene-by-gene approach. PCBP2, EBF2, and TNFRSF6 genes were 
overexpressed in osteosarcomas compared with normal samples, whereas PHLDA1 and 
TLE3 expression were decreased. Expression of PCBP1 and ADNP were unchanged. 
More importantly, EBF2 was one of the most overexpressed genes (R fold 5.75 and P = 





To elucidate the pathways altered in osteosarcoma, we performed network clustering of 
previously validated genes using the Ingenuity Software tool. Several significant 
networks were established with different scores (Supplementary Fig. S4). The most 
significant network includes 19 different genes functionally related with proliferation, 
cell death, and cancer. Among them, TNFRSF6, a decoy receptor for Fas ligand, which 
belongs to the main hub in this network, has been previously implicated in osteoblast 
differentiation survival and apoptosis (24). 
 
 
Characterization of TRAIL pathway 
 
EBF2 was one of the most significantly overexpressed genes in the osteosarcoma 
signature and it has been shown to act as transactivator of OPG in osteoblasts (14). We 
analyzed the OPG expression levels in an independent set of samples (P < 0.028; Fig. 
3). Osteosarcoma-derived cell lines secreted higher levels of OPG compared with 
control paired cells (P < 0.009). More importantly, ELISA assessment of OPG in 
conditioned medium of tumor cells was markedly increased compared with normal 
osteoblasts (Fig. 3). Of note, no such differences were found in populations with 
mutations in TP53. To validate these findings in an independent set of samples, we 
performed inmunohistochemistry in a osteosarcoma tissue microarray. 
Immunohistochemical analysis of a tissue microarray using an anti-EBF2 antibody 
revealed immunoreactivity in ~70% of osteosarcoma samples. EBF2 staining was 
predominantly nuclear despite strong cytoplasmic immunoreactivity (Fig. 3C). There 
was not correlation between staining intensity and prognosis (data not shown). 
 
To assess the direct involvement of EBF2 in OPG expression, we lentivirally transduced 
a high-expressing OPG osteosarcoma cell line (595B) with a short hairpin RNA 
targeting EBF2 to reduce EBF2 expression levels (Fig. 4). Knockdown of EBF2 
reduced mRNA levels ~50% to 70% compared with vector and control cells. We 
quantified OPG levels in the conditioned medium of these cell lines by ELISA. 
Interestingly, OPG levels were significantly reduced in EBF2 knockdown cells 
compared with vector and control cell lines (Fig. 4). These data indicate that increased 
levels of EBF2 transcription factor could be partially mediating OPG up-regulation in 
osteosarcoma cells. 
We then studied the implications of OPG levels in conditions of TRAIL-induced 
apoptosis. In the absence of OPG, the number of cells was decreased 48 h after 
treatment with TNF-α and TRAIL. In contrast, incubation with OPG substantially 
increased the survival after the proapoptotic induction with TNF-α or TRAIL alone 
(Fig. 4). We analyzed whether the previous effects on proliferation were due to 
apoptosis. Caspase-3 and -7 activities were increased after treatment with TNF-α and 
TRAIL. Interestingly, incubation with OPG dramatically decreased caspase activities of 
TRAIL-treated cells, whereas it displayed a residual effect on TNF- α-treated cells. 
Taken together, these data indicate that high OPG levels showed a protective effect in 






In this report, we have identified a transcriptomic signature by isolating chemonaive 
tumor-derived cell populations from patients diagnosed with sporadic osteosarcoma. 
Among this gene subset, the transcription factor EBF2 was found up-regulated in tumor 
samples. Similarly, its downstream target OPG, a RANK decoy receptor involved in 
osteoclast activation, showed higher expression levels in osteosarcoma-derived samples 
than paired control cells. More importantly, relative RANKL/OPG expression levels 
were lower in osteosarcoma samples than in normal osteoblasts (Supplementary Fig. 
S5). Thus, in the context of osteosarcoma, OPG overexpression may inhibit 
osteoclastogenesis, tilting the balance of bone turnover and favoring aberrant bone 
formation. 
 
Recently, in normal bone homeostasis, Kieslinger et al. showed that OPG was 
transcriptionally up-regulated by EBF2 (14). In contrast, OPG up-regulation in 
osteosarcoma did not totally correlate with EBF2 expression levels for all samples, 
suggesting other mechanisms of OPG regulation. Interestingly, Wnt signaling pathway, 
which has been found altered in osteosarcoma (25, 26), could strongly synergize with 
EBF2 to induce OPG (14). In this regard, several Wnt signaling components were 
deregulated in our gene signature. Similarly, samples harboring TP53 mutations 
displayed normal OPG levels despite their high EBF2 expression. This finding was 
intriguing because p53 knockout mice display higher levels of OPG. In contrast, 
activation of p53 led to a down-regulation of OPG in endothelial cells (27). Therefore, 
OPG up-regulation might involve other EBF2-independent mechanisms as suggested 
previously (28). 
 
Besides a role in normal bone homeostasis, OPG also acts as a decoy receptor for the 
cytotoxic effects induced by TRAIL in a variety of tumor cells with little effect on 
normal cells. TRAIL binds to its transmembrane receptors DcR4 and DcR5, which are 
expressed in normal and malignant cells. In addition to OPG, DcR1 and DcR2, which 
lack their intracellular death domain, act as decoy receptors preventing TRAIL-induced 
apoptosis. Both are highly expressed in normal cells but are almost absent in tumor cells 
(27). 
 
According to our findings, the ability of OPG to inhibit TRAIL-induced apoptosis might 
represent an important mechanism in promoting tumor cell survival. Indeed, TRAIL 
alone or in combination with radiotherapy and chemotherapy sensitizes tumor cells to 
apoptosis in osteosarcoma (29). In many other tumors (30, 31), OPG represents a 
survival factor in a TRAIL-independent manner and its overexpression increases cell 
proliferation and tumor growth in vivo (32). 
 
Paradoxically, recombinant OPG-Fc treatment in osteosarcoma models showed 
therapeutic benefits by blocking the RANK/RANKL system in the bone 
microenvironment and preventing tumor-induced osteolysis, without affecting tumor 
cell survival (33). This apparent discrepancy with our findings could be explained by 
the use of OPG truncated protein that lacks the death domains, the heparin-binding 
domain, and the dimerization sequences, which are required for the intracellular actions. 
One could speculate that specific OPG blocking antibodies against these domains could 
inhibit osteosarcoma-secreted OPG, potentiating TRAIL-mediated apoptosis (32). 
Besides OPG, other mechanisms involving prosurvival Bcl-2 proteins, such as Mcl-1, 
have been implicated in TRAIL resistance (34–36). Therefore, combined treatment 
targeting different mechanisms of TRAIL resistance could theoretically increase 
apoptotic response in vitro and improve clinical benefit. These speculations, however, 
need to be experimentally addressed in relevant animal models. Indeed, in vivo findings 
emphasize the tumor-inhibitory effect of a truncated OPG by blocking the 
RANK/RANKL axis (33, 37). These effects would be dependent on the relative 
concentrations, timing, and location of OPG, TRAIL, and RANKL expression in the 
bone microenvironment influenced by both normal and tumor cell types (38). Therefore, 
only by determining their in vitro expression levels in tumor cells would be difficult to 
anticipate the net balance of these players in the in vivo microenvironment. 
 
Our strategy circumvented several obstacles to discern the expression profile of 
transformed osteosarcoma cells specifically dissecting cell-autonomous effects. By 
isolating transformed cell populations, we avoided confounding effects of the 
surrounding stroma and inflammatory tissue, thus obviating non-cell-autonomous 
effects. In addition, the enrichment of the sample for tumor cells by serial passage 
(>20), the phenotypic characterization, and the abundant biological material that could 
be obtained from small diagnostic biopsies represent remarkable advantages over 
previous strategies. Other technologies such as confocal laser microdissection could 
facilitate the selection of tumor cells; however, low cellularity of many tumors and the 
RNA amplification step required are important drawbacks of this approach. In contrast, 
the isolation of transformed populations in early steps of tumorigenesis is the major 
advantage, avoiding the accumulation of chromosomal aberrations over time. This is 
supported by the fact that the comparative genomic hybridization profiling of the 
primary tumor samples used for the studies included herein revealed almost complete 
chromosomal integrity (data not shown). In stark contrast, samples isolated from 
advanced tumors showed a panoply of karyotypic alterations (39). 
 
Our strategy, with the inclusion of nontreated tumors and the use of stringent criteria in 
the statistical analysis, could partially explain the divergence in the transcriptomic gene 
signature obtained in other studies (10–13). Instead of focusing in a large collection of 
specimens with heterogeneous confounding stroma, a small number of homogenous 
samples derived from sporadic osteosarcoma patients provided strong clustering. The 
availability of paired-normal osteoblasts for all osteosarcoma patients provided a high-
quality control that allowed to minimize intraindividual and interindividual differences 
and provided further statistical strength. Thus, the identified signature yielded deep 
differences compared with previously described profiles (10–13). The top 
discriminators identified by Baird et al. for osteosarcoma (13) were not found in our 
gene subset. These included PPFIBP2, S100A13, and PTHR1 as well as osteoid-
associated genes: P4HA2, PLOD, COL5A1, and LUM. In contrast, members of the 
fibroblast growth factor receptor family, such as FGFR1, were also detected in our 
study. Similarly, one of the clusters found included the Wnt family members, which 
belong to a key pathway for skeletal and soft-tissue sarcomas (13). Several of the 
downstream players found among the top 30 discriminators in our analysis include 
FZD, TLE1, TLE3, and WNT. Perturbation of the Wnt signaling may lead to the 
abnormal osteoblast differentiation observed in vitro (25, 26). 
 
Nevertheless, some limitations inherent to our technical approach should also be 
considered. For instance, the isolation of tumor cells from its complex 
microenvironment might prevent the identification of important genes activated by 
tumor-stroma interactions such as members of the Notch pathway (40). In addition, this 
strategy is not adequate to detect key players, such as oncogenes activated by point 
mutations, or subtle changes in the levels of tumor suppressor genes involved in the 
carcinogenesis process. 
 
The identification of EBF2 and its validation in an independent set of tumor samples 
supports the validity of our approach. Future research will be required to further validate 
many other potential targets identified in this study. This information could be 
prospectively correlated with the response to chemotherapy or the metastatic outcome. 
This growing panel of well-characterized tumor-derived cells could also be used for 
testing novel therapeutics and identifying useful pharmacogenomic profiles that could 
lead to the use of tailored therapeutic regiments. Similar proof-of-principle could be use 
to study other pediatric and adult sarcomas. 
 
In summary, we have identified an osteosarcoma gene signature using a novel strategy. 
This transcriptomic signature revealed a key target EBF2 as commonly up-regulated in 
human osteosarcoma tumors. Induction of EBF2 could partially account for the OPG 
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 Table 1. Clinical, histopathologic, and molecular features of the osteosarcoma patients and tumor samples 
Patient Histology x-ray appearance 
Age 







473 Fibroblastic Osteolytic 15.08 M Tibia 95% Remission 74 66 Normal 
475 Osteoblastic Osteoblastic 23.5 F Femur 100% Remission 74 68 Normal 




491 Osteochondroblastic Osteoblastic 16.6 M Femur 90% Progression 69 20 Normal 
500 Osteoblastic Osteolytic 11 M Femur >90% Remission 68 59 Normal 
524 Osteochondroblastic Osteoblastic 11 F Femur <10% Remission 72 56 Normal 






























Table 2. Genes that were (P < 0.05) or tended to be (P = 0.05-0.09) differentially expressed in osteosarcomas 
 
cells compared with normal osteoblasts, further validated by Micro Fluidic Cards 
Probe-set 
ID 
TaqMan   
Assay 
Gene 
symbol Gene name P 
Fold 
change
214782_at Hs00193322_m1 CTTN Cortactin 0.0003 1.47 
200685_at Hs00191108_m1 SFRS11 Splicing factor, arginine/serine-rich 11 0.0003 1.73 
206187_at Hs00168765_m1 PTGIR Prostaglandin I2 (prostacyclin) receptor (IP) 0.0004 6.03 
205105_at Hs00159007_m1 MAN2A1 Mannosidase, a, class 2A, member 1 0.0006 2.55 
200668_s_at Hs00704312_s1 UBE2D3 Ubiquitin-conjugating enzyme E2D 3 0.0006 1.71 
218026_at Hs00360235_m1 HSPC009 HSPC009 protein 0.0012 1.56 
209708_at Hs00378239_m1 MOXD1 Monooxygenase, DBH-like 1 0.0012 11.39 
203221_at Hs00270768_m1 TLE1 Transducin-like enhancer of split 1 0.0012 2.62 
218517_at Hs00368739_m1 PHF17 PHD finger protein 17 0.0014 2.69 
201487_at Hs00175188_m1 CTSC Cathepsin C 0.0016 5.35 
201578_at Hs00193638_m1 PODXL Podocalyxin-like 0.0023 49.60 
202410_x_at Hs00171254_m1 IGF2 Insulin-like growth factor 2 (somatomedin A) 0.0024 0.36 
221901_at Hs00286734_m1 KIAA1644 KIAA1644 protein 0.0025 0.36 
201701_s_at Hs00175051_m1 PGRMC2 Progesterone receptor membrane component 2 0.0025 2.22 
213885_at Hs00197678_m1 TRIM3 Tripartite motif-containing 3 0.0025 1.43 
206702_at Hs00176096_m1 TEK TEK tyrosine kinase, endothelial 0.0030 11.76 
215029_at Hs00607590_m1 FLJ12666 Hypothetical protein FL]12666 0.0040 1.37 
221586_s_at Hs00231092_m1 E2F5 E2F transcription factor 5, p130-binding 0.0046 0.67 
200745_s_at Hs00181845_m1 GNB1 Guanine nucleotide binding protein, β polypeptide 1 0.0053 1.37 
213517_at Hs00245320_m1 PCBP2 Poly(rC) binding protein 2 0.0062 1.58 
210648_x_at Hs00601001_m1 SNX3 Sorting nexin 3 0.0071 1.80 
222282_at Hs00406243_m1 PAPD4 PAP-associated domain containing 4 0.0081 1.30 
220392_at Hs00224081_m1 EBF2 Early B-cell factor 2 0.0084 13.64 
213593_s_at Hs00203263_m1 TRA2A Transformer-2a 0.0093 1.47 
205803_s_at Hs00608195_m1 TRPC1 Transient receptor potential cation channel, subfamily C, member 1 0.0093 1.53 
215588_x_at Hs00187143_m1 RIOK3 RIO kinase 3 (yeast) 0.0107 1.63 
201722_s_at Hs00234919_m1 GALNT1 UDP-N-acetyl-a-D-galactosamine 0.0122 0.61 
208200_at Hs00174092_m1 IL1A Interleukin 1, a 0.0128 18.93 
213015_at Hs00220317_m1 BBX Bobby sox homologue (Drosophila) 0.0139 1.61 
203881_s_at Hs00187805_m1 DMD Dystrophin (muscular dystrophy, Duchenne and Becker types) 0.0158 4.90 
212672_at Hs00175892_m1 ATM Ataxia telangiectasia mutated 0.0179 1.54 
213791_at Hs00175049_m1 PENK Proenkephalin 0.0192 0.32 
212492_s_at Hs00392119_m1 JMJD2B ]umonji domain containing 2B 0.0203 1.38 
200769_s_at Hs00428515_g1 MAT2A Methionine adenosyltransferase II, a 0.0229 1.47 
205518_s_at Hs00379137_m1 CMAH CMP-N-acetylneuraminic acid hydroxylase 0.0258 3.72 
35436_at Hs00366395_m1 GOLGA2 Golgi autoantigen, golgin subfamily a, 2 0.0259 1.33 
203181_x_at Hs00177301_m1 SRPK2 SFRS protein kinase 2 0.0259 2.25 
209678_s_at Hs00702254_s1 PRKCI Protein kinase C, iota 0.0291 1.17 
204471_at Hs00176645_m1 GAP43 Growth-associated protein 43 0.0298 0.79 
220046_s_at Hs00220399_m1 CCNL1 Cyclin L1 0.0327 1.85 
207365_x_at Hs00739382_m1 WDR45 WD repeat domain 45 0.0350 1.59 
207186_s_at Hs00189461_m1 FALZ Fetal Alzheimer antigen 0.0459 1.76 
210407_at Hs00221372_m1 PPM1A Protein phosphatase 1A, magnesium-dependent, a isoform 0.0459 1.49 
208620_at Hs00362410_s1 PCBP1 Poly(rC) binding protein 1 0.0570 1.29 
205522_at Hs00429605_m1 HOXD4 Homeobox D4 0.0671 1.99 
206472_s_at Hs00183222_m1 TLE3 Transducin-like enhancer of split 3 0.0702 0.78 
204341_at Hs00414879_m1 TRIM16 Tripartite motif-containing 16 0.0702 0.84 
215404_x_at Hs00241111_m1 FGFR1 Fibroblast growth factor receptor 1 0.0777 1.48 





Figure 1. Histologic features of the tumors at diagnosis and morphology of derived 
cells in culture. A, histologic appearance of the tumor samples at diagnosis. B, 
representative morphology of two cell populations established in vitro from different 
tumors (left, 531 cells; right, 473 cells). Bar, 25 μm. 1. Patient #473; 2. Patient #475; 3. 






Figure 2. Hierarchical cluster diagram of differentially expressed genes in primary 
osteosarcoma cell populations versus paired-normal osteoblasts. Rows, single-gene 
probe-sets; columns, results from the single-microarray hybridizations. Each box is the 
hybridization signal value of a gene probeset in the microarray assay. The intensity of 
the color saturation in each probe-set box (ranging from 2 to 14 in log2 scale) provides a 
















Figure 3. A, detailed diagram of the microarray hybridization signals for the probe-set 
(220392_at) corresponding to the EBF2 gene in osteosarcoma paired control samples 
and quantitative RT-PCR for EBF2 in an independent set of osteosarcoma and normal 
osteoblast samples (n = 12). B, top, quantitative RT-PCR results for OPG expression 
levels; bottom, OPG protein levels in the conditioned medium of independent samples 
(control: n = 12 and osteosarcoma: n = 12) were analyzed by ELISA. C, representative 
images of immunohistochemical analysis of EBF2 in osteosarcoma sections. b to d, 






Figure 4. A, proliferation of osteosarcoma cells assessed by the MTT assay in the 
presence or absence of OPG after incubation for 48 h with TNF-α (25 ng/ mL), TRAIL 
(50 ng/mL), or in combination. B, caspase-3/7 activity after 24 h treatment with TNF-α 
or TRAIL after incubation with OPG (1 μg/mL). C, top, EBF2 silencing after lentiviral 
transduction of 595B cells with two specific short hairpin RNAs. Levels of EBF2 were 
quantified by specific RTPCR. Bottom, OPG protein was assessed by ELISA in culture 
supernatants of two different EBF2-silenced clones compared with control and vector 
transduced. *, P < 0.05; **, P < 0.001. 
 
 
 
